Try our Advanced Search for more refined results

Deals Rumor Mill: Mylan, Lear, Iliad

By Benjamin Horney ( August 20, 2014, 6:49 PM EDT) -- Generic-drug producer Mylan Inc. , undisclosed Indian drugmakers, and private equity firms TPG Capital LLP, Advent International, KKR & Co. LP and Warburg Pincus LLC have made it to the second round of bidding for a mature drug portfolio being offered by GlaxoSmithKline PLC, The Wall Street Journal reported Wednesday. GSK's portfolio includes prescription medicine brands — such as the antidepressant drug Paxil and the hepatitis B drug Zeffix — that have annual sales of about $1. 66 billion, according to WSJ. The sale price could end up being worth more than $3 billion, the report said. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

The 2025 AI Survey

Law firms are actively looking for ways to incorporate artificial intelligence into their workflow as it becomes ever more common. More than half of surveyed attorneys at U.S. law firms use generative AI for some purpose — up significantly from less than a third of attorneys who participated in the Law360 Pulse AI Survey last year.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!